After working in R&D at Groupe Renault for 3 years, Michel spent 7 years at Entrepreneur Invest, where he helped originate, structure, and support more than 20 expansion capital and LBO transactions, with a focus on innovative companies with distinctive expertise.
Michel joined Capital Export in 2017, after a rewarding experience as the General Manager of an export-based industrial SME. He offers both his investment experience and extensive knowledge of distinctive French companies that are key to Capital Export’s mission.
Michel is a graduate of ESSEC and ESTACA.
After 1 year of Private Equity experience with Initiative & Finance, Elise joined Capital Export in January 2019 to help launch Fund II, which had just completed its first investment.
Since then, Elise has participated in most of the Fund II transactions (particularly SFP, 2B Environnement, DSIA, Cabi Caillol, Proconect) and acquisitions (Global Media Santé for SFP, BM Environnement for 2B Environnement).
She has a Master’s degree in Corporate Finance from Audencia Business School.
Bone and ligament reconstruction
SBM (Science & BioMaterials) was founded in Lourdes, France in 1991. It offers a complete range of medical devices for sports and regenerative medicine and is known for its high-quality absorbable implants. Absorbable implants are used in arthroscopic surgery for ligament reconstructions (ACL), osteotomies around the knee, rotator cuff repair, and bone void filling.
Through its robust and continuous R&D policy, SBM has developed unique expertise in biocomposite materials to produce absorbable implants that combine mechanical resistance, elasticity, and osteoconduction. Only a handful of companies across the world master this technology, which offers proven benefits to orthopedic surgeons and patients during surgery and recovery. The management team will use Capital Export’s active support to boost SBM’s international development, particularly in Asia and the USA.
“The entire management team is thrilled to work with Capital Export and benefit from its expertise and network to support the company’s next phase of growth and international expansion.”
“SBM operates in high-growth markets driven by the rapid development of sports medicine, the aging population, illnesses caused by sedentary lifestyles, and patient preference for minimally invasive arthroscopic surgery, offering promising expansion opportunities. The company’s expertise across the entire value chain, in both medical and regulatory terms, combined with the talent of the team now led by Matthieu Souque, are sure to lead to success in this new stage.”